Vancomycin
Osteoporosis
University Hospital, Gentofte, CopenhagenSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Osteoporosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RISEDRONIC ACID Susan L. Greenspan | Phase 4 | BBB |
VITAMIN D Benha University | Phase 4 | BBB |
Zoledronate California Pacific Medical Center Research Institute | Phase 4 | BBB |
ALENDRONIC ACID University College Dublin | Phase 4 | BBB |
Medroxyprogesterone acetate Peking Union Medical College Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Vancomycin is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →